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INTRODUCTION 
Upper abdominal exenteration with organ transplantation 
has been used to treat a selected group of patients with 
non-resectable upper abdominal malignancies (1). with the 
exenteration, most of the structures deriving from the 
embryonal foregut are removed, allowing potentially complete 
circumscription of certain hepatic, bile duct cell, 
duodenal, gastric and pancreatic malignancies which may have 
spread to the surrounding lymph nodes or adjacent organs. 
PATIENTS AND METHODS 
The organs excised are the liver, 
stomach, duodenum, and variable portions 
colon. The organs replaced are variable. 
pancreas, spleen, 
of the proximal 
Three different 
transplantation replacement techniques have been used: 
liver-pancreas-duodenum 
liver only (modified 
islets (3). 
"en-block" (original cluster) (1), 
cluster) (2), and liver-pancreatic 
Original Cluster, (Group 1) 
Twenty one patients were treated with the original 
cluster procedure between July 1988 and January 1990 (group 
1). The indications are shown in Table 1. The patients were 
beyond help with conventional treatment, and in most of them 
resections, chemotherapy, irradiation, 
these modalities already had been tried. 
The first 15 patients of 
or combinations of 
this group had 
19 
20 
immunosuppression with cyclosporine, OKT3 induction with a 5 
or 10 day course, and prednisone to which azathioprine was 
added if needed. In the other 6 patients the 
immunosuppression was with FK 506 and steroids (4,5). 
Modified Cluster, (Group 2) 
Eighteen patients had the same exenteration but with 
liver placement only between April 1989 and December 1989. 
All the patients except one were treated with the same 
cyclosporine cocktail used in the first 15 patients of Group 
1. The exceptional patient was treated with FK 506 and 
steroids. The tumor diagnoses are shown in Table 2. 
Liver-Islets (Group 3) 
After abdominal exenteration, these 9 patients had 
liver replacement and pancreatic islet transplantation (3) 
under FK 506 and steroids between January 1990 and April 
1990. OKT3 was given if necessary to control rejection. 
The tumor diagnoses (Table 3) were similar to those in 
Groups 1 and 2. 
RESULTS 
Group 1 
After 11 to 29 months of follow-up, 8 of the 21 
patients are alive (38%) and 6 of them (28.5%) are free of 
recurrence (Table 1). Seven of the 9 deaths resulted from 
technical complications and infections, usually at an early 
time. Tumor recurrence occurred later and was responsible 
for 6 deaths (Table 
metastases beyond the 
1) . Two 
resection 
of these 
margins at 
patients had 
the time of 
operation. The best survival was of patients with sarcomas 
and neuroendocrine tumors, and the poorest with duct cell 
carcinomas. positive lymph nodes in the specimen was a poor 
prognostic finding. 
TABLE 1 
Primary Pathology 
7 Duct Cell CA 
4 Carcinoid 
3 Sarcoma 
2 Cholangio CA 
2 HCC 
1 Adenoca Gallbladder 
1 Adenoca Colon 
1 Neuroendocrine 
Alive NED 
1 1 
3 2 
3 2 
1 1 
0 0 
0 0 
0 0 
0 0 
AWD 
0 
1 
1 
0 
0 
0 
0 
0 
DOD 
3 
o 
o 
o 
1 
1 
1 
o 
TABLE 1 --- Survival by diagnosis in the original cluster 
patients (Group 1). NED = no evidence of disease, AWD = 
alive with disease, DOD = dead of disease. 
Group 2 
with a follow-up ranging between 12 and 20 months, 6 
patients are alive (33%) and 4 of them (22%) are free of 
recurrence. The causes of death, time of death, and 
prognostic influence of tumor diagnosis were no different 
than in Group 1 (Table 2). As in Group 1, some patients (2 
examples) had metastatic tumors beyond the resection margins 
at the time of operation but this was not appreciated until 
later. 
TABLE 2 
Primary Pathology Alive NED AWD DOD 
9 Cholangio CA 4 3 1 2 
6 HCC 0 0 0 5 
1 Carcinoid 1 1 0 0 
1 Leiomyosarcoma 1 0 1 0 
1 Neuroendocrine 0 0 0 1 
TABLE 2 --- Survival by diagnosis in the modified cluster 
patients (Group 2). For legend, see Table 1. 
Group 3 
six of the 9 patients are alive after 8 to 11 months of 
follow-up. One patient died of recurrent cancer after 178 
days, and 2 others died earlier from infection; all three 
were insulin dependent at the time of death. Of the 6 
21 
22 
patients who are alive, 4 are without evidence of tumor 
recurrence and all 6 are insulin free. Table 3 shows the 
survival by tumor diagnosis. 
TABLE 3 
Primary Pathology Alive NED AWD DOD 
2 cholangio CA 2 2 0 0 
2 Adenoca Pancreas 1 1 0 0 
2 HCC 1 1 0 1 
1 Sarcoma 1 0 1 0 
1 Adenoca Colon 1 0 1 0 
1 Neuroendocrine 0 0 0 0 
TABLE 3 Survival by diagnosis in the liver and 
pancreatic islet patients (Group 3). For legend, see Table 
1. 
DISCUSSION 
These operations had a high mortality from technical 
complications which always led to infections. In Group 1 
recipients, the pancreas component of the graft was 
responsible for 4 fatal complications: pancreatitis and 
pancreatic abscess (2), and pancreatitis and rupture of an 
arterial pseudoaneurysm (2). Severe weight loss was 
observed in patients of all 3 groups and those in Groups 2 
and 3 required prolonged parenteral hyperalimentation (in 
some to the present time). Group 2 patients had the further 
handicap of being diabetic. Control of this complication in 
Group 3 patients by islet transplantation was noteworthy. 
The use of FK 506 seemed to make the control of 
rejection easier, but the case material was too limited and 
complex to allow comparisons with cyclosporine cocktail 
regimens. Patients treated with FK 506 (6 in Group 1, one 
in Group 2, and 9 in Group 3) had very low steroid 
requirements compared to those treated with conventional 
immunosuppression. Acute rejection usually could be reversed 
with a bolus of methylprednisolone and increased doses of FK 
506. In an FK patient of Group I, graft versus host disease 
(GVHD) was unequivocally diagnosed with sex kharyotyping 
performed by in situ hybridization of the Y chromosome; the 
donor was a male and the recipient female. She was treated 
successfully with increased steroid therapy. 
The type and the extent of tumor were the chief non-
technical factors influencing later survival. Patients who 
had macroscopic or microscopic lymph-node involvement had a 
very high rate of recurrence. However, our experience 
suggests that a selected group of patients could benefit 
from this radical surgical approach. Afterwards, adjuvant 
chemotherapy or irradiation should be considered. 
The nutritional problems suffered by patients in all 3 
groups (especially Groups 2 and 3) suggest that future 
trials may require the addition of a gastric component to 
the replacement graft. This would have to be placed in 
mainstream continuity with the alimentary tract. Such new 
options may become feasible with the better 
immunosuppression made possible with FK 506 (4,5). 
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